
Neuland Laboratories Limited
Sanali Info Park, 'A' Block,
Ground Floor, 8-2-120/113
Road No. 2, Banjara Hills
Hyderabad - 500 034.
Telangana, India.

Tel: 040 30211600 / 23551081
Fax: 040 30211602
Email: neuland@neulandlabs.com
www.neulandlabs.com

September 12, 2017

To
B S E Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

To
The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 001

Scrip Code: 524558

**Scrip Code: NEULANLAB
Series: EQ**

Dear Sirs,

Sub: Compliance with Regulation 47 (1) (b) of the SEBI Listing Regulations, 2015

Please find attached herewith copies of the newspaper publication of Un-audited financial results for the quarter ended June 30, 2017, published in Financial Express and Andhra Prabha on September 12, 2017 for your reference.

Thanking you,

Yours faithfully,
For Neuland Laboratories Limited


Sarada Bhamidipati
Company Secretary



Encl : as above

NEULAND LABORATORIES LIMITED			
(CIN : L85195TG1984PLC004393)			
Regd. office: Sanali Info Park, 'A' Block, Ground Floor 8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034			
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2017			
(Amount in lakhs of ₹ unless otherwise stated)			
		Quarter Ended	
Sl. No.	Particulars	30.06.2017 (Unaudited)	30.06.2016 (Unaudited)
1	Revenue		
	(a) Revenue from operations	11,748.07	15,152.23
	(b) Other Income	265.90	52.82
	Total Revenue	12,013.97	15,205.05
2	Expenses		
	(a) Cost of materials consumed	6,003.02	6,970.72
	(b) Excise duty	172.79	175.63
	(c) Changes in inventories of finished goods and work-in-progress	(1,075.34)	79.14
	(d) Employee benefits expense	1,912.24	1,670.64
	(e) Finance costs	476.57	636.24
	(f) Depreciation and amortisation expense	510.22	436.07
	(g) Manufacturing expenses	1,937.95	1,462.10
	(h) Sales promotion expenses including sales commission	644.33	1,512.20
	(i) Other expenses	1,089.34	830.70
	Total Expenses	11,671.12	13,773.44
3	Profit before tax (1-2)	342.85	1,431.61
4	Tax expense		
	(a) Current tax	184.75	511.59
	(b) Deferred tax benefit	(71.68)	(30.83)
5	Profit for the period (3-4)	229.78	950.85
6	Other comprehensive income (net of taxes)		
	(a) Items that will not be reclassified to profit or loss		
	(i) Re-measurement losses on defined benefit plans	(5.56)	(5.56)
	(b) Items that will be reclassified to profit or loss		
	Total comprehensive income	224.22	945.29
7	Paid-up Equity Share Capital (Face value of ₹10 per share)	895.49	895.39
8	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)		
	(a) Basic (refer note 6)	2.59	10.70
	(b) Diluted (refer note 6)	2.59	10.70

NOTES:

- The above unaudited financial results have been reviewed by the Audit Committee, approved and taken on record by the Board of Directors at their meeting held on September 11, 2017. The results for the quarter ended 30 June 2017 presented were subjected to a "Limited Review" by the Statutory Auditor's of the Company. An unqualified report was issued by them thereon. The financial results and other information for the quarter ended 30 June 2016 has neither been subjected to a limited review nor audit by the statutory auditors.
- The Company adopted Indian Accounting Standards ("Ind AS") from 1 April 2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. Financial results for corresponding period presented have been prepared in accordance with the recognition and measurement principles of Ind AS 24.
- The operations of the Company are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments".
- Reconciliation between financial results as previously reported under Previous GAAP and Ind AS for the quarter ended 30 June 2016:

Particulars	Amount (₹ in lakhs)
Net profit under previous GAAP	971.13
Interest on borrowings from related parties	(21.07)
Recognition of rental income at fair value	3.48
Remeasurement of employee benefits	(4.48)
Others	(5.49)
Deferred tax benefit	7.29
Total net profit for the period under Ind AS	950.85
Other comprehensive income	(5.56)
Total comprehensive income	945.29

- In November 2016, the Board of Directors of the Company approved a Scheme for amalgamation of its parent company Neuland Health Sciences Private Limited (NHSP) and a fellow subsidiary Neuland Pharma Research Private Limited (NPRPL) with the Company. The Scheme of amalgamation has been drawn in accordance with the provisions of the Companies Act, 2013 pursuant to which and subject to requisite regulatory approvals, the entire business undertakings of NHSP and NPRPL will be transferred to the Company with effect from 1 April 2016. Further, pursuant to the terms of the scheme, the Company shall cancel 4,590,608 equity shares presently held by its parent company NHSP, and it shall allot the fresh equity share capital to the shareholders of NHSP and NPRPL in the following ratio duly determined by independent valuation experts:
 - 552 equity shares of the Company of ₹10 each, fully paid-up for every 1,000 equity shares of NHSP of ₹10 each, fully paid up and;
 - 410 equity shares of the Company of ₹10 each, fully paid-up for 100 equity shares of NPRPL of ₹10 each, fully paid up.
 As at the date of approval of this statement, the Scheme of amalgamation has been duly approved by the Securities and Exchange Board of India, shareholders, creditors of the Company and is subject to and pending for the requisite approvals, sanctions, consents, observations, clearances from the National Company Law Tribunal. The process of obtaining pending approvals is currently under progress. Although the scheme, on obtaining the requisite approvals, shall be effective from 1 April 2016, however, pending final regulatory approvals and clearances and to comply with the Listing (Obligations and Disclosures) Regulations, 2015 the accompanying statement for the three months period ended 30 June 2017 have been prepared without giving any effect of the proposed transfer of business undertakings of NPRPL and NHSP.
- EPS for the quarters is not annualized.

By Order of the Board
For Neuland Laboratories Limited
Sd/-
Dr.D.R.Rao
Chairman and Managing Director
(DIN 00107737)

Place: Hyderabad
Date : 11 September, 2017

NEULAND LABORATORIES LIMITED			
(CIN : L85195TG1984PLC004393)			
Regd. office: Sanali Info Park, 'A' Block, Ground Floor 8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034			
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2017			
(Amount in lakhs of ₹ unless otherwise stated)			
		Quarter Ended	
Sl. No.	Particulars	30.06.2017 (Unaudited)	30.06.2016 (Unaudited)
1	Revenue		
	(a) Revenue from operations	11,748.07	15,152.23
	(b) Other Income	265.90	52.82
	Total Revenue	12,013.97	15,205.05
2	Expenses		
	(a) Cost of materials consumed	6,003.02	6,970.72
	(b) Excise duty	172.79	175.63
	(c) Changes in inventories of finished goods and work-in-progress	(1,075.34)	79.14
	(d) Employee benefits expense	1,912.24	1,670.64
	(e) Finance costs	476.57	636.24
	(f) Depreciation and amortisation expense	510.22	436.07
	(g) Manufacturing expenses	1,937.95	1,462.10
	(h) Sales promotion expenses including sales commission	644.33	1,512.20
	(i) Other expenses	1,089.34	830.70
	Total Expenses	11,671.12	13,773.44
3	Profit before tax (1-2)	342.85	1,431.61
4	Tax expense		
	(a) Current tax	184.75	511.59
	(b) Deferred tax benefit	(71.68)	(30.83)
5	Profit for the period (3-4)	229.78	950.85
6	Other comprehensive income (net of taxes)		
	(a) Items that will not be reclassified to profit or loss		
	(i) Re-measurement losses on defined benefit plans	(5.56)	(5.56)
	(b) Items that will be reclassified to profit or loss		
	Total comprehensive income	224.22	945.29
7	Paid-up Equity Share Capital (Face value of ₹10 per share)	895.49	895.39
8	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)		
	(a) Basic (refer note 6)	2.59	10.70
	(b) Diluted (refer note 6)	2.59	10.70

NOTES:

- The above unaudited financial results have been reviewed by the Audit Committee, approved and taken on record by the Board of Directors at their meeting held on September 11, 2017. The results for the quarter ended 30 June 2017 presented were subjected to a "Limited Review" by the Statutory Auditor's of the Company. An unqualified report was issued by them thereon. The financial results and other information for the quarter ended 30 June 2016 has neither been subjected to a limited review nor audit by the statutory auditors.
- The Company adopted Indian Accounting Standards ("Ind AS") from 1 April 2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. Financial results for corresponding period presented have been prepared in accordance with the recognition and measurement principles of Ind AS 24.
- The operations of the Company are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments".
- Reconciliation between financial results as previously reported under Previous GAAP and Ind AS for the quarter ended 30 June 2016:

Particulars	Amount (₹ in lakhs)
Net profit under previous GAAP	971.13
Interest on borrowings from related parties	(21.07)
Recognition of rental income at fair value	3.48
Remeasurement of employee benefits	(4.48)
Others	(5.49)
Deferred tax benefit	7.29
Total net profit for the period under Ind AS	950.85
Other comprehensive income	(5.56)
Total comprehensive income	945.29

- In November 2016, the Board of Directors of the Company approved a Scheme for amalgamation of its parent company Neuland Health Sciences Private Limited (NHSP) and a fellow subsidiary Neuland Pharma Research Private Limited (NPRPL) with the Company. The Scheme of amalgamation has been drawn in accordance with the provisions of the Companies Act, 2013 pursuant to which and subject to requisite regulatory approvals, the entire business undertakings of NHSP and NPRPL will be transferred to the Company with effect from 1 April 2016. Further, pursuant to the terms of the scheme, the Company shall cancel 4,590,608 equity shares presently held by its parent company NHSP, and it shall allot the fresh equity share capital to the shareholders of NHSP and NPRPL in the following ratio duly determined by independent valuation experts:
 - 552 equity shares of the Company of ₹10 each, fully paid-up for every 1,000 equity shares of NHSP of ₹10 each, fully paid up and;
 - 410 equity shares of the Company of ₹10 each, fully paid-up for 100 equity shares of NPRPL of ₹10 each, fully paid up.
 As at the date of approval of this statement, the Scheme of amalgamation has been duly approved by the Securities and Exchange Board of India, shareholders, creditors of the Company and is subject to and pending for the requisite approvals, sanctions, consents, observations, clearances from the National Company Law Tribunal. The process of obtaining pending approvals is currently under progress. Although the scheme, on obtaining the requisite approvals, shall be effective from 1 April 2016, however, pending final regulatory approvals and clearances and to comply with the Listing (Obligations and Disclosures) Regulations, 2015 the accompanying statement for the three months period ended 30 June 2017 have been prepared without giving any effect of the proposed transfer of business undertakings of NPRPL and NHSP.
- EPS for the quarters is not annualized.

By Order of the Board
For Neuland Laboratories Limited
Sd/-
Dr.D.R.Rao
Chairman and Managing Director
(DIN 00107737)

Place: Hyderabad
Date : 11 September, 2017